Franklin Biotechnology Discovery Fund A (FBDIX)
178.68
-3.47
(-1.90%)
USD |
Oct 06 2026
Returns Chart
Key Stats
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 1.01% | 1.216B | 0.31% | 38.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -50.38M | 29.90% |
Basic Info
| Investment Strategy | |
| The Fund seeks to provide capital appreciation. Under normal market conditions, the Fund predominantly invests in equity securities and invests at least 80% of its net assets in securities of biotechnology companies(at least 50% of its earnings derived from biotechnology activities) and discovery research firms. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Multi Cap Growth |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Franklin Templeton |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
16
-691.44M
Peer Group Low
647.63M
Peer Group High
1 Year
% Rank:
68
-50.38M
-1.850B
Peer Group Low
2.180B
Peer Group High
3 Months
% Rank:
21
-329.09M
Peer Group Low
1.097B
Peer Group High
3 Years
% Rank:
62
-6.864B
Peer Group Low
969.40M
Peer Group High
6 Months
% Rank:
57
-1.113B
Peer Group Low
1.056B
Peer Group High
5 Years
% Rank:
64
-9.084B
Peer Group Low
971.41M
Peer Group High
YTD
% Rank:
67
-1.246B
Peer Group Low
974.03M
Peer Group High
10 Years
% Rank:
68
-12.63B
Peer Group Low
5.623B
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of October 07, 2026.
Asset Allocation
As of August 31, 2026.
| Type | % Net |
|---|---|
| Cash | -0.09% |
| Stock | 52.68% |
| Bond | 0.00% |
| Convertible | 0.00% |
| Preferred | 0.83% |
| Other | 46.58% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
|
Other Assets less Liabilities
|
45.74% | -- | -- |
| Jazz Pharmaceuticals Plc | 2.75% | 231.19 | -0.09% |
| Amgen, Inc. | 2.52% | 413.02 | 2.59% |
| argenx SE | 2.25% | 929.15 | -0.15% |
| Gilead Sciences, Inc. | 2.23% | 146.82 | 1.80% |
| Vertex Pharmaceuticals, Inc. | 2.08% | 505.57 | 0.65% |
| Regeneron Pharmaceuticals, Inc. | 2.03% | 742.18 | 0.47% |
| Revolution Medicines, Inc. | 1.70% | 200.94 | 0.53% |
| AstraZeneca PLC | 1.47% | 160.16 | 0.98% |
| Ascendis Pharma A/S | 1.45% | 228.62 | 1.14% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | 0.25% |
| Actual Management Fee | 0.60% |
| Administration Fee | -- |
| Maximum Front Load | 5.50% |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | 0.00% |
| General Availability | |
| Available for Insurance Product | No |
| Available for RRSP | No |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 1000.00 None |
| Minimum Subsequent Investment | 0.00 None |
TTM Distributions
| Type | Oct | Nov | Dec | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Qualified Income
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Normal
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Qualified
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
LT Cap Gains
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Ordinary Income
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Non-Qual
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
ST Cap Gains
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Interest
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Tax-Exempt
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
ROC
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Other
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Total
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
As of September 30, 2026.
Basic Info
| Investment Strategy | |
| The Fund seeks to provide capital appreciation. Under normal market conditions, the Fund predominantly invests in equity securities and invests at least 80% of its net assets in securities of biotechnology companies(at least 50% of its earnings derived from biotechnology activities) and discovery research firms. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Multi Cap Growth |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Franklin Templeton |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (10-6-26) | 1.96% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | 116 |
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:FBDIX", "name") |
| Broad Asset Class: =YCI("M:FBDIX", "broad_asset_class") |
| Broad Category: =YCI("M:FBDIX", "broad_category_group") |
| Prospectus Objective: =YCI("M:FBDIX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |